Literature DB >> 12538164

A functional genomics approach to Kaposi's sarcoma.

Ashlee V Moses1, Michael A Jarvis, Camilo Raggo, Yolanda C Bell, Rebecca Ruhl, B G Mattias Luukkonen, Diana J Griffith, Cecily L Wait, Brian J Druker, Michael C Heinrich, Jay A Nelson, Klaus Fruh.   

Abstract

Kaposi's sarcoma (KS) is the most frequent malignancy afflicting acquired immune-deficiency syndrome (AIDS) patients. Tumor lesions are characterized by spindle cells of vascular origin and vascularization. Kaposi's sarcoma-associated herpes virus (KSHV) is consistently found in all forms of KS. Infection of dermal microvascular endothelial cells (DMVEC) with KSHV recapitulates spindle cell formation in vitro. We studied this transformation process by DNA microarray analysis comparing the RNA expression profiles of KSHV-infected and mock-infected DMVEC. Genes involved in tumorigenesis, angiogenesis, host defense, cell growth and differentiation, transcription, and metabolism were observed to change significantly upon infection with KSHV. One of the most consistently KSHV-induced genes was the receptor tyrosine kinase and proto-oncogene c-Kit. Inhibition of c-Kit activity with the pharmacological inhibitor of c-Kit signaling STI571 reversed the KSHV-induced morphological transformation of DMVEC. Moreover, overexpression studies showed that c-Kit was sufficient to induce spindle cell formation (Moses et al. J. Virol. 76(16): 8383-8399). These data demonstrate that microarrays are useful for the identification of pharmacological targets essential for KS tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12538164     DOI: 10.1111/j.1749-6632.2002.tb05951.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

Review 1.  Role of gene expression arrays in sarcomas.

Authors:  Keith M Skubitz; Amy P N Skubitz
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

2.  Virus and cell RNAs expressed during Epstein-Barr virus replication.

Authors:  Jing Yuan; Ellen Cahir-McFarland; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells.

Authors:  Todd M Bull; Christina A Meadows; Christopher D Coldren; Mark Moore; Sylk M Sotto-Santiago; Serge P Nana-Sinkam; Thomas B Campbell; Mark W Geraci
Journal:  Am J Respir Cell Mol Biol       Date:  2008-06-27       Impact factor: 6.914

4.  Viral interleukin-6 encoded by rhesus macaque rhadinovirus is associated with lymphoproliferative disorder (LPD).

Authors:  B U Orzechowska; M Manoharan; J Sprague; R D Estep; M K Axthelm; S W Wong
Journal:  J Med Primatol       Date:  2009-10       Impact factor: 0.667

5.  Characterization of c-Kit expression and activation in KSHV-infected endothelial cells.

Authors:  Janet L Douglas; Jill G Whitford; Ashlee V Moses
Journal:  Virology       Date:  2009-06-06       Impact factor: 3.616

6.  Insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  Patrick P Rose; Matthew Bogyo; Ashlee V Moses; Klaus Früh
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

Review 7.  Systems biology and the host response to viral infection.

Authors:  Seng-Lai Tan; Gopinath Ganji; Bryan Paeper; Sean Proll; Michael G Katze
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

8.  Proteins of the secretory pathway govern virus productivity during lytic gammaherpesvirus infection.

Authors:  J Mages; K Freimüller; R Lang; A K Hatzopoulos; S Guggemoos; U H Koszinowski; H Adler
Journal:  J Cell Mol Med       Date:  2008-01-11       Impact factor: 5.310

9.  C-Kit, CD34 & α-SMA Immunohistochemical Features in Classic Kaposi Sarcoma and Kaposiform Hemangioendothelioma.

Authors:  Eiman A Hasby; Nehal El Mashad; Rania Eltatawy
Journal:  J Microsc Ultrastruct       Date:  2016-06-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.